Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations.

Research output: Contribution to journalArticle

Standard

Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations. / Baliakas, Panagiotis; Agathangelidis, Andreas; Hadzidimitriou, Anastasia; Sutton, Lesley-Ann; Minga, Eva; Tsanousa, Athina; Scarfò, Lydia; Davis, Zadie; Yan, Xiao-Jie; Shanafelt, Tait; Plevova, Karla; Sandberg, Yorick; Vojdeman, Fie Juhl; Boudjogra, Myriam; Tzenou, Tatiana; Chatzouli, Maria; Chu, Charles C; Veronese, Silvio; Gardiner, Anne; Mansouri, Larry; Smedby, Karin E; Pedersen, Lone Bredo; Moreno, Denis; Van Lom, Kirsten; Giudicelli, Véronique; Francova, Hana Skuhrova; Nguyen-Khac, Florence; Panagiotidis, Panagiotis; Juliusson, Gunnar; Angelis, Lefteris; Anagnostopoulos, Achilles; Lefranc, Marie-Paule; Facco, Monica; Trentin, Livio; Catherwood, Mark; Montillo, Marco; Geisler, Christian H; Langerak, Anton W; Pospisilova, Sarka; Chiorazzi, Nicholas; Oscier, David; Jelinek, Diane F; Darzentas, Nikos; Belessi, Chrysoula; Davi, Frederic; Ghia, Paolo; Rosenquist, Richard; Stamatopoulos, Kostas.

In: Blood, Vol. 125, No. 5, 2015, p. 856-859.

Research output: Contribution to journalArticle

Harvard

Baliakas, P, Agathangelidis, A, Hadzidimitriou, A, Sutton, L-A, Minga, E, Tsanousa, A, Scarfò, L, Davis, Z, Yan, X-J, Shanafelt, T, Plevova, K, Sandberg, Y, Vojdeman, FJ, Boudjogra, M, Tzenou, T, Chatzouli, M, Chu, CC, Veronese, S, Gardiner, A, Mansouri, L, Smedby, KE, Pedersen, LB, Moreno, D, Van Lom, K, Giudicelli, V, Francova, HS, Nguyen-Khac, F, Panagiotidis, P, Juliusson, G, Angelis, L, Anagnostopoulos, A, Lefranc, M-P, Facco, M, Trentin, L, Catherwood, M, Montillo, M, Geisler, CH, Langerak, AW, Pospisilova, S, Chiorazzi, N, Oscier, D, Jelinek, DF, Darzentas, N, Belessi, C, Davi, F, Ghia, P, Rosenquist, R & Stamatopoulos, K 2015, 'Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations.', Blood, vol. 125, no. 5, pp. 856-859. https://doi.org/10.1182/blood-2014-09-600874

APA

Baliakas, P., Agathangelidis, A., Hadzidimitriou, A., Sutton, L-A., Minga, E., Tsanousa, A., ... Stamatopoulos, K. (2015). Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations. Blood, 125(5), 856-859. https://doi.org/10.1182/blood-2014-09-600874

CBE

Baliakas P, Agathangelidis A, Hadzidimitriou A, Sutton L-A, Minga E, Tsanousa A, Scarfò L, Davis Z, Yan X-J, Shanafelt T, Plevova K, Sandberg Y, Vojdeman FJ, Boudjogra M, Tzenou T, Chatzouli M, Chu CC, Veronese S, Gardiner A, Mansouri L, Smedby KE, Pedersen LB, Moreno D, Van Lom K, Giudicelli V, Francova HS, Nguyen-Khac F, Panagiotidis P, Juliusson G, Angelis L, Anagnostopoulos A, Lefranc M-P, Facco M, Trentin L, Catherwood M, Montillo M, Geisler CH, Langerak AW, Pospisilova S, Chiorazzi N, Oscier D, Jelinek DF, Darzentas N, Belessi C, Davi F, Ghia P, Rosenquist R, Stamatopoulos K. 2015. Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations. Blood. 125(5):856-859. https://doi.org/10.1182/blood-2014-09-600874

MLA

Vancouver

Baliakas P, Agathangelidis A, Hadzidimitriou A, Sutton L-A, Minga E, Tsanousa A et al. Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations. Blood. 2015;125(5):856-859. https://doi.org/10.1182/blood-2014-09-600874

Author

Baliakas, Panagiotis ; Agathangelidis, Andreas ; Hadzidimitriou, Anastasia ; Sutton, Lesley-Ann ; Minga, Eva ; Tsanousa, Athina ; Scarfò, Lydia ; Davis, Zadie ; Yan, Xiao-Jie ; Shanafelt, Tait ; Plevova, Karla ; Sandberg, Yorick ; Vojdeman, Fie Juhl ; Boudjogra, Myriam ; Tzenou, Tatiana ; Chatzouli, Maria ; Chu, Charles C ; Veronese, Silvio ; Gardiner, Anne ; Mansouri, Larry ; Smedby, Karin E ; Pedersen, Lone Bredo ; Moreno, Denis ; Van Lom, Kirsten ; Giudicelli, Véronique ; Francova, Hana Skuhrova ; Nguyen-Khac, Florence ; Panagiotidis, Panagiotis ; Juliusson, Gunnar ; Angelis, Lefteris ; Anagnostopoulos, Achilles ; Lefranc, Marie-Paule ; Facco, Monica ; Trentin, Livio ; Catherwood, Mark ; Montillo, Marco ; Geisler, Christian H ; Langerak, Anton W ; Pospisilova, Sarka ; Chiorazzi, Nicholas ; Oscier, David ; Jelinek, Diane F ; Darzentas, Nikos ; Belessi, Chrysoula ; Davi, Frederic ; Ghia, Paolo ; Rosenquist, Richard ; Stamatopoulos, Kostas. / Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations. In: Blood. 2015 ; Vol. 125, No. 5. pp. 856-859.

RIS

TY - JOUR

T1 - Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations.

AU - Baliakas, Panagiotis

AU - Agathangelidis, Andreas

AU - Hadzidimitriou, Anastasia

AU - Sutton, Lesley-Ann

AU - Minga, Eva

AU - Tsanousa, Athina

AU - Scarfò, Lydia

AU - Davis, Zadie

AU - Yan, Xiao-Jie

AU - Shanafelt, Tait

AU - Plevova, Karla

AU - Sandberg, Yorick

AU - Vojdeman, Fie Juhl

AU - Boudjogra, Myriam

AU - Tzenou, Tatiana

AU - Chatzouli, Maria

AU - Chu, Charles C

AU - Veronese, Silvio

AU - Gardiner, Anne

AU - Mansouri, Larry

AU - Smedby, Karin E

AU - Pedersen, Lone Bredo

AU - Moreno, Denis

AU - Van Lom, Kirsten

AU - Giudicelli, Véronique

AU - Francova, Hana Skuhrova

AU - Nguyen-Khac, Florence

AU - Panagiotidis, Panagiotis

AU - Juliusson, Gunnar

AU - Angelis, Lefteris

AU - Anagnostopoulos, Achilles

AU - Lefranc, Marie-Paule

AU - Facco, Monica

AU - Trentin, Livio

AU - Catherwood, Mark

AU - Montillo, Marco

AU - Geisler, Christian H

AU - Langerak, Anton W

AU - Pospisilova, Sarka

AU - Chiorazzi, Nicholas

AU - Oscier, David

AU - Jelinek, Diane F

AU - Darzentas, Nikos

AU - Belessi, Chrysoula

AU - Davi, Frederic

AU - Ghia, Paolo

AU - Rosenquist, Richard

AU - Stamatopoulos, Kostas

PY - 2015

Y1 - 2015

N2 - An unresolved issue in chronic lymphocytic leukemia (CLL) is whether IGHV3-21 gene usage, in general, or the expression of stereotyped B-cell receptor immunoglobulin defining subset #2 (IGHV3-21/IGLV3-21), in particular, determines outcome for IGHV3-21-utilizing cases. We reappraised this issue in 8593 CLL patients of whom 437 (5%) used the IGHV3-21 gene with 254/437 (58%) classified as subset #2. Within subset #2, immunoglobulin heavy variable (IGHV)-mutated cases predominated, whereas non-subset #2/IGHV3-21 was enriched for IGHV-unmutated cases (P = .002). Subset #2 exhibited significantly shorter time-to-first-treatment (TTFT) compared with non-subset #2/IGHV3-21 (22 vs 60 months, P = .001). No such difference was observed between non-subset #2/IGHV3-21 vs the remaining CLL with similar IGHV mutational status. In conclusion, IGHV3-21 CLL should not be axiomatically considered a homogeneous entity with adverse prognosis, given that only subset #2 emerges as uniformly aggressive, contrasting non-subset #2/IGVH3-21 patients whose prognosis depends on IGHV mutational status as the remaining CLL.

AB - An unresolved issue in chronic lymphocytic leukemia (CLL) is whether IGHV3-21 gene usage, in general, or the expression of stereotyped B-cell receptor immunoglobulin defining subset #2 (IGHV3-21/IGLV3-21), in particular, determines outcome for IGHV3-21-utilizing cases. We reappraised this issue in 8593 CLL patients of whom 437 (5%) used the IGHV3-21 gene with 254/437 (58%) classified as subset #2. Within subset #2, immunoglobulin heavy variable (IGHV)-mutated cases predominated, whereas non-subset #2/IGHV3-21 was enriched for IGHV-unmutated cases (P = .002). Subset #2 exhibited significantly shorter time-to-first-treatment (TTFT) compared with non-subset #2/IGHV3-21 (22 vs 60 months, P = .001). No such difference was observed between non-subset #2/IGHV3-21 vs the remaining CLL with similar IGHV mutational status. In conclusion, IGHV3-21 CLL should not be axiomatically considered a homogeneous entity with adverse prognosis, given that only subset #2 emerges as uniformly aggressive, contrasting non-subset #2/IGVH3-21 patients whose prognosis depends on IGHV mutational status as the remaining CLL.

U2 - 10.1182/blood-2014-09-600874

DO - 10.1182/blood-2014-09-600874

M3 - Article

VL - 125

SP - 856

EP - 859

JO - Blood

JF - Blood

SN - 1528-0020

IS - 5

ER -